



SAFETY DATA SHEET

Revision date 17-Jun-2025

Version 3

Page 1 / 15

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Cytarabine Injection, solution (Hospira, inc.)
Product Code(s) PZ03474
Trade Name: Not applicable
Chemical Family: Mixture

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as Antineoplastic

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Germ cell mutagenicity

Category 1B - (H340)

Reproductive toxicity

Category 1B - (H360D)

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements



Signal word

Danger

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 2 / 15
Version 3

Hazard statements

H340 - May cause genetic defects
H360D - May damage the unborn child

Precautionary Statements - EU (§28, 1272/2008)

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves and protective clothing
P308 + P313 - IF exposed or concerned: Get medical advice/attention
P405 - Store locked up
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Cytarabine (CAS #: 147-94-4)	2-10	-	205-705-9	Muta. 1B (H340) Repr. 1B (H360D)	Not classified	No data available	No data available
SODIUM CHLORIDE (CAS #: 7647-14-5)	*	-	231-598-3	Not classified	Not classified	No data available	No data available
Sodium hydroxide (CAS #: 1310-73-2)	**	-	215-185-5 (011-002-00-6)	Skin Corr. 1A (H314)	Eye Irrit. 2 :: 0.5%<=C<2% Skin Corr. 1A :: C>=5% Skin Corr. 1B :: 2%<=C<5% Skin Irrit. 2 :: 0.5%<=C<2%	No data available	No data available
+ Hydrochloric Acid	**	-	231-595-7	Press. Gas	Eye Irrit. 2 ::	No data	No data

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 3 / 15
Version 3

(CAS #: 7647-01-0)			(017-002-00-2) (017-002-01-X)	Skin Corr. 1A (H314) Acute Tox. 3 (H331)	10%≤C<25% Skin Corr. 1B :: C≥25% Skin Irrit. 2 :: 10%≤C<25% STOT SE 3 :: C≥10%	available	available
--------------------	--	--	----------------------------------	---------------------------------------------------	--------------------------------------------------------------------------------------------------	-----------	-----------

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	*	-	231-791-2	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate No information available

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Cytarabine 147-94-4	>3000	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3550	10000	No data available	No data available	No data available
Sodium hydroxide 1310-73-2	325	1350	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

This product does not contain candidate substances of very high concern at a concentration ≥0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

* Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret. Non-hazardous ingredients provided for completeness.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 4 / 15
Version 3

medical attention.

Ingestion

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians

None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media

Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical

Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products

Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders

Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment

Prevent further leakage or spillage if safe to do so.

Methods for cleaning up

Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Prevention of secondary hazards

Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 5 / 15
Version 3

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions

Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s)

Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Cytarabine

Pfizer OEL TWA-8 Hr: 2 µg/m³

SODIUM CHLORIDE

Latvia

TWA: 5 mg/m³;

Russia

MAC: 5 mg/m³

Sodium hydroxide

ACGIH OEL (Ceiling)

2 mg/m³

ACGIH TLV

Ceiling: 2 mg/m³

Austria

TWA-TMW: 2 mg/m³; inhalable fraction

STEL-KZGW: 4 mg/m³ (8 X 5 min); inhalable fraction

Bulgaria

TWA: 2.0 mg/m³; alkaline aerosols

Czech Republic

1 mg/m³

Ceiling: 2 mg/m³

Denmark

Ceiling: 2 mg/m³;

Estonia

TWA: 1 mg/m³;

STEL: 2 mg/m³;

Finland

Ceiling: 2 mg/m³;

France

2 mg/m³

Hungary

TWA-AK: 1 mg/m³;

STEL-CK: 2 mg/m³;

Ireland

STEL: 2 mg/m³;

Ceiling Limit Value

2 mg/m³

Latvia

TWA: 0.5 mg/m³;

Poland

TWA-NDS: 0.5 mg/m³;

STEL-NDSch: 1 mg/m³;

Romania

TWA: 1 mg/m³;

STEL: 3 mg/m³;

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 6 / 15
Version 3

Slovakia	TWA: 2 mg/m ³ ;
Spain	STEL (VLA-EC): 2 mg/m ³ ;
Switzerland	TWA-MAK: 2 mg/m ³ ; inhalable dust
	STEL-KZGW: 2 mg/m ³ ; inhalable dust
OSHA PEL	TWA: 2 mg/m ³
	(vacated) Ceiling: 2 mg/m ³
United Kingdom	STEL: 2 mg/m ³ ;
+ Hydrochloric Acid	
ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	TWA-TMW: 5 ppm;
	TWA-TMW: 8 mg/m ³ ;
	STEL-KZGW: 10 ppm (8 X 5 min);
	STEL-KZGW: 15 mg/m ³ (8 X 5 min);
Bulgaria	TWA: 5 ppm;
	TWA: 8.0 mg/m ³ ;
	STEL: 10 ppm;
	STEL: 15.0 mg/m ³ ;
Czech Republic	8 mg/m ³
	Ceiling: 15 mg/m ³
Denmark	STEL: 5 ppm;
	STEL: 8 mg/m ³ ;
Estonia	TWA: 5 ppm;
	TWA: 8 mg/m ³ ;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
European Union	TWA: 5 ppm;
	TWA: 8 mg/m ³ ;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
Finland	STEL: 5 ppm;
	STEL: 7.6 mg/m ³ ;
Germany DFG	TWA-MAK: 2 ppm; I(2);
	TWA-MAK: 3.0 mg/m ³ ; I(2);
	Peak: 4 ppm;
	Peak: 6 mg/m ³ ;
Germany TRGS	TWA-AGW; 2 ppm (exposure factor 2);
	TWA-AGW; 3 mg/m ³ (exposure factor 2);
Hungary	TWA-AK: 8 mg/m ³ ;
	TWA-AK: 5 ppm;
	STEL-CK: 165 mg/m ³ ;
	STEL-CK: 10 ppm;
Ireland	TWA: 8 mg/m ³ ;
	TWA: 5 ppm;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
Italy MDLPS	TWA: 5 ppm;
	TWA: 8 mg/m ³ ;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
Ceiling Limit Value	2 ppm
	3.0 mg/m ³
Latvia	TWA: 5 ppm;
	TWA: 8 mg/m ³ ;
	STEL: 10 ppm;
	STEL: 15 mg/m ³ ;
Netherlands	TWA: 5 ppm;
	TWA: 8 mg/m ³ ;

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 7 / 15
Version 3

	STEL: 10 ppm; STEL: 15 mg/m ³ ; TWA-NDS: 5 mg/m ³ ; STEL-NDSch: 10 mg/m ³ ;
Poland	TWA: 5 ppm; TWA: 8 mg/m ³ ; STEL: 10 ppm; STEL: 15 mg/m ³ ;
Romania	MAC: 5 mg/m ³ TWA: 5 ppm; TWA: 8.0 mg/m ³ ; Ceiling: 15 mg/m ³ ;
Russia	TWA-(VLA-ED): 5 ppm; TWA-(VLA-ED): 7.6 mg/m ³ ; STEL (VLA-EC): 10 ppm; STEL (VLA-EC): 15 mg/m ³ ;
Slovakia	TWA-MAK: 2 ppm; TWA-MAK: 3 mg/m ³ ; STEL-KZGW: 4 ppm; STEL-KZGW: 6 mg/m ³ ;
Spain	5 ppm 7 mg/m ³
Switzerland	Ceiling: 5 ppm Ceiling: 7 mg/m ³ (vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m ³
U.S. - OSHA - Final PELs - Ceiling Limits	TWA: 1 ppm; gas and aerosol mist TWA: 2 mg/m ³ ; gas and aerosol mist STEL: 5 ppm; gas and aerosol mist STEL: 8 mg/m ³ ; gas and aerosol mist
OSHA PEL	
United Kingdom	

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

8.2. Exposure controls

Engineering controls

General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 8 / 15
Version 3

Hand protection	Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious disposable protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).
Thermal hazards	No information available.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	Solution
Physical state	Liquid
Color	Colorless
Odor	No information available.
Odor threshold	No information available

<u>Property</u>	<u>Values</u>
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	No data available
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
--------------------------	---------

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 9 / 15
Version 3

Molecular weight

Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity

No information available.

10.2. Chemical stability

Stability

Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid

Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials

As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information:

The information included in this section describes the potential hazards of the individual ingredients

Short term

May cause eye and skin irritation (based on components)

Long Term:

Animal studies have shown a potential to cause adverse effects on the fetus.

Known Clinical Effects:

Bone marrow suppression is the most serious adverse effect seen during clinical use. Adverse effects seen in clinical use include gastrointestinal discomfort, dizziness, and headache.

Acute toxicity

Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation

Based on available data, the classification criteria are not met.

Skin corrosion/irritation

Based on available data, the classification criteria are not met.

Respiratory or skin sensitization

Based on available data, the classification criteria are not met.

STOT - single exposure

Based on available data, the classification criteria are not met.

STOT - repeated exposure

Based on available data, the classification criteria are not met.

Reproductive toxicity

May damage the unborn child.

Germ cell mutagenicity

May cause genetic defects.

Carcinogenicity

Based on available data, the classification criteria are not met.

Aspiration hazard

Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Cytarabine

Rat Oral LD 50 > 3000 mg/kg

Rat Para-periosteal LD 50 > 5000 mg/kg

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 10 / 15
Version 3

Mouse Oral LD 50 3150 mg/kg
Mouse Intravenous LD 50 > 7000 mg/kg

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Cytarabine	> 5 g/kg (Rat)	-	-
SODIUM CHLORIDE	= 3550 mg/kg (Rat)	> 10000 mg/kg (Rabbit)	> 42 mg/L (Rat) 1 h
Sodium hydroxide	= 325 mg/kg (Rat)	= 1350 mg/kg (Rabbit)	-
+ Hydrochloric Acid	238 - 277 mg/kg (Rat)	> 5010 mg/kg (Rabbit)	= 1.68 mg/L (Rat) 1 h

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Cytarabine

Eye Irritation Rabbit Minimal

Skin Irritation Rabbit Mild

SODIUM CHLORIDE

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

Sodium hydroxide

Eye Irritation Rabbit Severe

Skin Irritation Rabbit Severe

+ Hydrochloric Acid

Skin irritation Severe

Eye irritation Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Cytarabine

Embryo / Fetal Development Mouse >= 2 mg/kg/day LOAEL Teratogenic

Embryo / Fetal Development Rat 20 mg/kg LOAEL Teratogenic

Embryo / Fetal Development Rat 50 mg/kg LOAEL Developmental toxicity

Embryo / Fetal Development Mouse 8 mg/kg/day LOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cytarabine

In Vivo Chromosome Aberration Rodent Bone Marrow Positive

In Vivo Sister Chromatid Exchange Rodent liver Positive

In Vivo Micronucleus Mouse Positive

In Vitro Chromosome Aberration Human Lymphocytes Positive

In Vitro Human Lymphocytes Positive

+ Hydrochloric Acid

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vivo Micronucleus Rat Negative

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 11 / 15
Version 3

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Cytarabine

72 Week(s) Rat Oral 25 mg/kg/day NOAEL Not carcinogenic

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

+ Hydrochloric Acid

IARC

Group 3

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment should be avoided.

12.1. Toxicity

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment Based on available data, the classification criteria are not met.

Chemical name	PBT and vPvB assessment
SODIUM CHLORIDE	Not PBT/vPvB PBT assessment does not apply
Sodium hydroxide	Not PBT/vPvB PBT assessment does not apply
+ Hydrochloric Acid	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 12 / 15
Version 3

12.7. Other adverse effects

Other adverse effects

No information available.

PMT or vPvM properties

Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Cytarabine

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Developmental
EINECS	205-705-9
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

SODIUM CHLORIDE

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-598-3
AICS	Present

Sodium hydroxide

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 13 / 15
Version 3

CERCLA/SARA Section 313 de minimus %	Not Listed
Hazardous Substances RQs	1000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	215-185-5
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6
+ Hydrochloric Acid	
CERCLA/SARA Section 313 de minimus %	1.0 %
Hazardous Substances RQs	5000 lb
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-595-7
AICS	Present
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 5 Schedule 6

National regulations

Chemical name	French RG number
SODIUM CHLORIDE 7647-14-5	RG 78

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)

Not applicable

TRGS 905

Not applicable

Chemical name	Netherlands - List of Carcinogens	Netherlands - List of Mutagens	Netherlands - List of Reproductive Toxins
Cytarabine 147-94-4	-	-	Development Category 1B

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable

Storage of Hazardous Material

Not applicable

WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20

Not applicable

Major Accidents Ordinance SR 814.012

Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Sodium hydroxide 1310-73-2	75	-
+ Hydrochloric Acid 7647-01-0	75	-

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 14 / 15
Version 3

Persistent Organic Pollutants

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid 7647-01-0	25	250

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Chemical name	EU - Plant Protection Products (1107/2009/EC)
SODIUM CHLORIDE 7647-14-5	Plant protection agent

Chemical name	Biocidal Products Regulation (EU) No 528/2012 (BPR)
SODIUM CHLORIDE 7647-14-5	Product-type 1: Human hygiene
+ Hydrochloric Acid 7647-01-0	Product-type 2: Disinfectants and algicides not intended for direct application to humans or animals

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing Chemicals Inventory

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

NZIoC - New Zealand Inventory of Chemicals

TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H360D - May damage the unborn child H340 - May cause genetic defects H314 - Causes severe skin burns and eye damage H331

- Toxic if inhaled

Data Sources: Publicly available toxicity information.

Reason for revision Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on

SAFETY DATA SHEET

Product Name Cytarabine Injection, solution (Hospira, inc.)
Revision date 17-Jun-2025

Page 15 / 15
Version 3

Ingredients. Updated Section 6 - Accidental Release Measures. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 16 - Other Information.

Revision date 17-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.